Who is sponsoring NCT00127530?

NCT00127530 is sponsored by Acorda Therapeutics.

What condition does NCT00127530 study?

NCT00127530 studies Multiple Sclerosis.

What drugs are being tested in NCT00127530?

Interventions: Fampridine-SR, Placebo.

What is the status of NCT00127530?

NCT00127530 is currently COMPLETED.

Last reviewed 2018-08-13 · How we verify

Double-Blind, Placebo-Controlled, 21-Week, Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR in Subjects With Multiple Sclerosis

NCT00127530 Phase 3 COMPLETED Results posted

To assess the safety and efficacy of 10 milligram (mg) twice a day (b.i.d.) Fampridine-SR in patients diagnosed with multiple sclerosis (MS), in a double-blind, placebo-controlled, parallel group study.

Details

Lead sponsor	Acorda Therapeutics
Phase	Phase 3
Status	COMPLETED
Enrolment	300
Start date	2005-05
Completion	2006-09

Conditions

Multiple Sclerosis

Interventions

Fampridine-SR
Placebo

Primary outcomes

Timed Walk Responders (Patients Who Showed Consistent Improvement on the Timed-25 Foot Walk) — Days 14, 42, 70 and 98 of treatment, corresponding to the four on-drug visits during double-blind treatment period.
Patients who showed a faster walking speed for at least three of the four on-drug visits during the double-blind treatment period as compared to the maximum speed for any of the five off-drug visits.

Countries

United States, Canada